
    
      This is a prospective, non-randomized, single-arm, multi-centre surveillance study to be
      conducted in Europe.

      The Surveillance is designed as a study, where

        -  ARISE AV is prescribed in the usual manner in accordance with the terms of the approval.

        -  Assignment of the patient to a particular therapeutic strategy is not decided in advance
           by this Surveillance Protocol but falls within current practice and the prescription of
           ARISE AV is clearly separated from the decision to include the patient in the
           Surveillance.

        -  No additional diagnostic or monitoring procedures shall be applied to the patients.

        -  and epidemiological methods shall be used for the analysis of collected data.
    
  